The Valley Desk

Clinical trial reportClinical pharmacology in drug developmentPublished

A Phase 1, Open-Label, Single-Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Clinical trial report
Venue
Clinical pharmacology in drug development
Published
Subject terms
Humans; Liver Diseases; Pyrazoles; Quinoxalines; Receptors, Fibroblast Growth Factor; Protein Kinase Inhibitors; Administration, Oral; Severity of Illness Index; Area Under Curve; Adult; Aged; Middle Aged
PubMed ID
42057702
PubMed Central ID
PMC13129628
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal